Navigation Links
Gleevec Pushes Advanced Melanoma Into Remission
Date:4/17/2008

Woman's case first showing the cancer may have an Achilles' heel, report suggests

THURSDAY, April 17 (HealthDay News) -- The cancer drug Gleevec has forced metastatic melanoma into remission for the first time, report researchers at the Dana-Farber Cancer Institute in Boston.

The case involves a 79-year-old woman with melanoma tumors in several parts of her abdomen. The tumor cells carried an abnormality in a gene called KIT, so the patient was enrolled in a clinical trail of the drug imatinib (Gleevec), which targets the KIT gene.

Four weeks after the woman started therapy, there was dramatic reduction in tumor size and metabolism. Two of the tumor masses had vanished, and several others were much smaller. After four months, the tumors were still in check and, nine months later, the women was still taking the drug and her condition remained stable.

The report was published in the April 20 issue of the Journal of Clinical Oncology.

"This is the first proof of principle that we can find an Achilles' heel in melanoma and by targeting that gene with a drug, cause the [tumor cells] to die. It is especially exciting because there haven't been any effective treatments for melanoma patients with metastatic disease," study author Dr. Stephen Hodi said in a prepared statement.

He said this case may involve just one patient, but should inspire new hope in the fight against melanoma. Because previous research failed to identify any genetic weak point that could be targeted to stop melanoma cell growth, some researchers believed that no such Achilles' heel existed for melanoma cells. The discovery of this one suggests there may be others.

"Dramatic remissions in metastatic melanoma are something that, as physicians, we've rarely seen. Confirming these results will require enrolling additional patients in clinical trials -- something we're actively working to accomplish," Hodi said.

More information

The U.S. National Cancer Institute has more about melanoma.



-- Robert Preidt



SOURCE: Dana-Farber Cancer Institute, news release, April 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Gleevec May Disrupt Ovarian Function
2. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
3. Gleevec, the targeted cancer pill, delivers more good news to patients
4. Arizona Senate Pushes for Smoking Cessation Treatments for State Medicaid Beneficiaries
5. Pedometer Pushes People to Walk More
6. Depression Pushes Middle-Aged Workers to Retire
7. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
8. HHS Names First Director of the Biomedical Advanced Research Development Authority
9. Advanced Life Sciences to Host Conference Call to Discuss April 7th Meeting with FDA
10. Cato Research Ltd. and Advanced Targeting Systems, Inc. Partner to Develop SP-SAP for Chronic Pain
11. Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new ... the Bible about helping to stop cancer. Yisrayl says there are too many suffering and ... health and science industries will pay close attention and take action. The Pastor says that ...
(Date:5/6/2016)... ... 06, 2016 , ... In honor of Military Spouse Appreciation ... and the National Military Family Association, a nonprofit that works to strengthen and ... scholarship recipient of 2016. , “Being awarded this scholarship by Career Step, ...
(Date:5/6/2016)... ... 06, 2016 , ... Kenneth Cochran, DSc, RN, FACHE, President/CEO ... the South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular Institute ... Guided Coronary Atherectomy. , This procedure involves the removal of plaque ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, ... Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and ... Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue ...
(Date:5/5/2016)... , ... May 05, 2016 , ... While the practice ... paid to the impact our aging population has on communities and resources. Aging Life ... plan for and face age-related challenges. , Aging Life Care is a holistic, ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016  Diagnostic imaging has been ... to concerns that these tests cause health care costs to ... imaging, as well as the adoption of new ... medical peripherals that help health care providers cut costs, while ... medical imaging is a renowned authorized reseller of the ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Thalassaemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights - 2016, provides ... epidemiology, Thalassaemia market valuations and forecast, Thalassaemia ...
(Date:5/4/2016)... NESS ZIONA, Israel , May ... BVXV, TASE: BVXV) announced today that BiondVax,s CEO, Dr. ... 2016 conference in New York City . ... presenting at 10:30am at Pioneers 2016, a conference presented by ... New York Palace Hotel. The BiondVax presentation that ...
Breaking Medicine Technology: